Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening

A. T. Hesselink; C. J.L.M. Meijer; M. Poljak; J. Berkhof; F. J. Van Kemenade; M. L. Van Der Salm; M. Bogaarts; P. J.F. Snijders; D. A.M. Heideman

doi:10.1128/JCM.00633-13

Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening

A. T. Hesselink
, C. J.L.M. Meijer
, M. Poljak
, J. Berkhof
, F. J. Van Kemenade
, M. L. Van Der Salm
, M. Bogaarts
, P. J.F. Snijders
, D. A.M. Heideman^*

^*Corresponding author for this work

VU University Medical Center
Institute for Economic Research

Research output: Contribution to journal › Article › Academic › peer-review

44 Citations (Scopus)

Abstract

This study showed that the Abbott RealTime High RiskHPVassay fulfilled cross-sectional clinical equivalence and reproducibility criteria of international consensus guidelines, which indicates that this assay can be considered clinically validated for cervical cancer screening purposes.

Original language	English
Pages (from-to)	2409-2410
Number of pages	2
Journal	Journal of Clinical Microbiology
Volume	51
Issue number	7
DOIs	https://doi.org/10.1128/JCM.00633-13
Publication status	Published - Jul 2013
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1128/JCM.00633-13

Cite this

Hesselink, A. T., Meijer, C. J. L. M., Poljak, M., Berkhof, J., Van Kemenade, F. J., Van Der Salm, M. L., Bogaarts, M., Snijders, P. J. F., & Heideman, D. A. M. (2013). Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. Journal of Clinical Microbiology, 51(7), 2409-2410. https://doi.org/10.1128/JCM.00633-13

@article{1a777a83409d444095df8122ce180a9f,

title = "Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening",

abstract = "This study showed that the Abbott RealTime High RiskHPVassay fulfilled cross-sectional clinical equivalence and reproducibility criteria of international consensus guidelines, which indicates that this assay can be considered clinically validated for cervical cancer screening purposes.",

author = "Hesselink, \{A. T.\} and Meijer, \{C. J.L.M.\} and M. Poljak and J. Berkhof and \{Van Kemenade\}, \{F. J.\} and \{Van Der Salm\}, \{M. L.\} and M. Bogaarts and Snijders, \{P. J.F.\} and Heideman, \{D. A.M.\}",

year = "2013",

month = jul,

doi = "10.1128/JCM.00633-13",

language = "English",

volume = "51",

pages = "2409--2410",

journal = "Journal of Clinical Microbiology",

issn = "0095-1137",

publisher = "American Society for Microbiology",

number = "7",

}

Hesselink, AT, Meijer, CJLM, Poljak, M, Berkhof, J, Van Kemenade, FJ, Van Der Salm, ML, Bogaarts, M, Snijders, PJF & Heideman, DAM 2013, 'Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening', Journal of Clinical Microbiology, vol. 51, no. 7, pp. 2409-2410. https://doi.org/10.1128/JCM.00633-13

Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening. / Hesselink, A. T.; Meijer, C. J.L.M.; Poljak, M. et al.
In: Journal of Clinical Microbiology, Vol. 51, No. 7, 07.2013, p. 2409-2410.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening

AU - Hesselink, A. T.

AU - Meijer, C. J.L.M.

AU - Poljak, M.

AU - Berkhof, J.

AU - Van Kemenade, F. J.

AU - Van Der Salm, M. L.

AU - Bogaarts, M.

AU - Snijders, P. J.F.

AU - Heideman, D. A.M.

PY - 2013/7

Y1 - 2013/7

N2 - This study showed that the Abbott RealTime High RiskHPVassay fulfilled cross-sectional clinical equivalence and reproducibility criteria of international consensus guidelines, which indicates that this assay can be considered clinically validated for cervical cancer screening purposes.

AB - This study showed that the Abbott RealTime High RiskHPVassay fulfilled cross-sectional clinical equivalence and reproducibility criteria of international consensus guidelines, which indicates that this assay can be considered clinically validated for cervical cancer screening purposes.

UR - https://www.scopus.com/pages/publications/84879456680

U2 - 10.1128/JCM.00633-13

DO - 10.1128/JCM.00633-13

M3 - Article

C2 - 23637297

AN - SCOPUS:84879456680

SN - 0095-1137

VL - 51

SP - 2409

EP - 2410

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

IS - 7

ER -

Clinical validation of the Abbott RealTime high risk HPV assay according to the guidelines for human papillomavirus DNA test requirements for cervical screening

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this